Japan PHarmacological Audit study of Safety and Efficacy in Real world (Phase-R) Nausea and Vomiting Study

Japan PHarmacological Audit study of Safety and Efficacy in Real world (Phase-R) Nausea and Vomiting Study - Phase-R Nausea and Vomiting Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020493

Enrollment

100

Registered

2016-01-12

Start date

2016-01-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients with cancer being cared for by hospital palliative care teams aged 18 years or older who receive olanzapine treatment for nausea and vomiting

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
average nausea NRS on day 2	—

Secondary

Measure	Time frame
adverse events symptom relief scale	—

Countries

Japan

Contacts

Public ContactKeisuke Ariyoshi

The University of Tokyo, The Institute of Medical Science Department of Palliative Medicine

k-ariyoshi@umin.ac.jp03-3443-8111

Outcome results